FDA Qualifies MolecuLightDX, Forging a Fast Lane for Wound Care Innovation

PITTSBURGH, PA – January 29, 2026 – The U.S. Food and Drug Administration (FDA) has officially qualified the MolecuLightDX® wound measurement system as a Medical Device Development Tool (MDDT), a landmark decision poised to significantly accelerate the development of new wound care technologies. This qualification establishes the device as a trusted, standardized tool for use in clinical trials, providing a clear and predictable pathway for companies seeking regulatory approval for innovative treatments.

MolecuLight announced today that its device's quantitative wound measurement function is now validated for use as a response biomarker. This allows researchers and medical device sponsors to generate reliable, FDA-accepted data on treatment effectiveness, a critical step in bringing new products to market. The qualification is a rare distinction; since the MDDT program's inception in 2017, only 20 tools have earned this status, with MolecuLightDX being the first and only wound care device that is both FDA Class II cleared for clinical use and MDDT qualified for research.

A New Standard for Measuring Healing

The FDA's MDDT program was created to streamline medical device development by qualifying scientifically rigorous tools that can produce reliable measurements for specific contexts of use. By pre-validating a tool like MolecuLightDX, the agency eliminates the need for individual sponsors to prove the validity of their measurement methods in every new submission, a process that can be both time-consuming and costly.

This qualification effectively creates a new gold standard for measuring changes in wound size, a primary endpoint in nearly all studies of healing. Previously, researchers relied on a variety of methods, from simple rulers to disparate digital systems, often leading to variability in data and uncertainty during regulatory review. The MDDT designation provides an objective, non-contact, and reproducible “measuring stick” that ensures consistency across different studies and product evaluations.

For a device to be qualified, it must undergo a stringent evaluation of its scientific evidence to prove it can produce plausible and accurate measurements. The MolecuLightDX system, which is already FDA-cleared for its primary function of detecting elevated bacterial loads in wounds using fluorescence imaging, has now demonstrated that its digital measurement capabilities meet this high bar. This dual capability positions it as a comprehensive assessment tool, providing insights into both the bacterial status and the physical progression of a wound.

Streamlining the Path from Lab to Bedside

The most immediate impact of this qualification will be felt in the research and development sector. Companies working on the next generation of wound dressings, skin substitutes, topical agents, and therapeutic devices now have a clear, FDA-sanctioned method for demonstrating their product's efficacy. This reduces regulatory risk and can significantly shorten the timeline from initial concept to market availability.

"The FDA's qualification of MolecuLightDX as an MDDT reflects the strength of our clinical evidence and the agency's confidence in the accuracy and reproducibility of our wound measurement technology," said Anil Amlani, Chief Executive Officer of MolecuLight, in a statement. "This designation enables researchers and sponsors to use MolecuLightDX as a standardized, trusted measurement tool in wound healing studies, accelerating innovation and improving patient outcomes."

This acceleration is critical in a field addressing chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure injuries, which affect millions of Americans and represent a significant burden on the healthcare system. By making clinical trials more efficient and predictable, the MDDT qualification is expected to foster a more competitive and innovative landscape, ultimately benefiting patients who await more effective treatment options.

Beyond the Ruler: A Clinical Shift to Objective Data

While the MDDT qualification directly impacts research, it also reinforces a broader clinical shift away from subjective wound assessment towards objective, data-driven care. For decades, clinicians have relied on visual inspection and manual measurements with rulers to track wound healing, methods prone to human error and inter-observer variability. The MolecuLightDX provides a stark contrast, capturing high-resolution images and calculating wound area, depth, and volume with digital precision.

The device’s utility is backed by an extensive body of evidence, with over 100 peer-reviewed publications supporting its effectiveness. Its core fluorescence imaging technology allows clinicians to visualize, in real-time, wounds containing elevated bacterial loads (greater than 10⁴ Colony Forming Units per gram), a key factor that can impair or stall the healing process. This immediate feedback helps guide decisions on debridement, antimicrobial stewardship, and overall treatment strategy.

By combining this diagnostic capability with MDDT-qualified measurement, the MolecuLightDX offers a holistic view of wound status. This move toward precision medicine in wound care allows for more personalized and timely interventions, helping to avoid complications and improve healing trajectories. The FDA's endorsement of its measurement accuracy further solidifies the device's role as an indispensable tool in modern wound management.

A Strategic Moat in a Competitive Market

For MolecuLight, this qualification is a significant strategic victory that solidifies its leadership in the advanced wound care market. While other companies offer digital wound measurement systems, none carry the weight of an FDA MDDT qualification. This unique status creates a powerful competitive advantage, making MolecuLightDX a highly attractive, if not essential, partner for any organization conducting serious wound care research.

This designation could drive widespread adoption of the device within the clinical research organization (CRO) and medical device R&D communities. The assurance that data generated by the device will be accepted by the FDA makes it a low-risk, high-value asset for any clinical trial budget. This could create a new and substantial revenue stream for the privately held company.

The FDA's decision also aligns with broader regulatory trends favoring digital health technologies, validated biomarkers, and other tools that can make medical product development more efficient and scientifically robust. By qualifying MolecuLightDX, the agency is not only endorsing a specific technology but also signaling its commitment to modernizing the evaluation of medical devices, particularly in complex areas like wound healing. This move paves the way for a future where new, life-changing wound care treatments can reach patients faster than ever before.